| 0.04 -0.015 (-27.27%) | 12-20 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.14  |
1-year : | 0.22 |
| Resists | First : | 0.12 |
Second : | 0.19 |
| Pivot price | 0.05 |
|||
| Supports | First : | 0.01 |
Second : | 0.01 |
| MAs | MA(5) : | 0.03 |
MA(20) : | 0.06 |
| MA(100) : | 0.3 |
MA(250) : | 0.96 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.2 |
D(3) : | 9.2 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 3.35 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMPL ] has closed above bottom band by 14.1%. Bollinger Bands are 70.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.04 - 0.04 | 0.04 - 0.04 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Thu, 18 Apr 2024
Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Movies UK
Tue, 19 Dec 2023
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to ... - PR Newswire
Tue, 05 Dec 2023
Impel Pharmaceuticals hit by another C-suite departure - Puget Sound Business Journal - The Business Journals
Thu, 23 Nov 2023
Impel Pharma (NASDAQ: IMPL) up 140%, down again 22% - Welcome to Meme World - Dhaka Tribune
Fri, 17 Nov 2023
Impel Pharmaceuticals Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Sun, 05 Nov 2023
Impel Pharmaceuticals CEO Adrian Adams steps down - Puget Sound Business Journal - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 71.6 (%) |
| Shares Short | 852 (K) |
| Shares Short P.Month | 809 (K) |
| EPS | -3.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.87 |
| Profit Margin | 0 % |
| Operating Margin | -255.1 % |
| Return on Assets (ttm) | -62.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 63 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.87 |
| EBITDA (p.s.) | -2.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -79 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0.01 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|